Shenzhen Hepalink Pharmaceutical Group Co., Ltd.

Symbol: 002399.SZ

SHZ

10.37

CNY

Market price today

  • -22.1544

    P/E Ratio

  • -0.5380

    PEG Ratio

  • 13.66B

    MRK Cap

  • 0.01%

    DIV Yield

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (002399-SZ) Stock Price & Analysis

Shares Outstanding

0M

Gross Profit Margin

0.32%

Operating Profit Margin

-0.08%

Net Profit Margin

-0.13%

Return on Assets

-0.04%

Return on Equity

-0.06%

Return on Capital Employed

-0.03%

Company general description and statistics

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
CEO:Mr. Li Li
Full-time employees:2080
City:Shenzhen
Address:No. 21 Langshan Road
IPO:2010-05-06
CIK:

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. engages in the manufacture and sale of pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally. The company operates through four segments: Finished dose pharmaceutical products, Active Pharmaceutical Ingredients (API), Contract Development and Manufacturing Organization, and Others. Its pharmaceutical products consist of finished dose pharmaceutical products, which primarily include enoxaparin sodium injection; API products, including heparin sodium API and enoxaparin sodium API; and other products, such as pancreatin API. The company is also involved in the provision of research and development, manufacturing, quality management, and program management services; and development and manufacture of recombinant pharmaceutical products, critical non-viral vectors, intermediates for gene therapy, and naturally derived pharmaceutical products. In addition, it engages in property management, investment management and consulting, biopharmaceutical technology development and consulting, and equity and venture investment activities; research, development, and production of biopharmaceuticals; production and sale of heparin sodium; provision of services on pharmaceutical related activities; and trading of medical and biopharmaceutical products. The company was formerly known as Shenzhen Hepalink Pharmaceutical Co.,Ltd. and changed its name to Shenzhen Hepalink Pharmaceutical Group Co., Ltd. in February 2017. Shenzhen Hepalink Pharmaceutical Group Co., Ltd. was founded in 1998 and is headquartered in Shenzhen, the People's Republic of China.

General Outlook

When we look at how much money they make before expenses, they keep 0.323% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is -0.083%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of -0.126%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust -0.037% return, is a testament to Shenzhen Hepalink Pharmaceutical Group Co., Ltd.'s adeptness in optimizing resource deployment. Shenzhen Hepalink Pharmaceutical Group Co., Ltd.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -0.057%. Furthermore, the proficiency of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. in capital utilization is underscored by a remarkable -0.032% return on capital employed.

Liquidity Ratios

Analyzing 002399.SZ liquidity ratios reveals its financial health of the firm. The current ratio of 226.27% gauges short-term asset coverage for liabilities. The quick ratio (81.49%) assesses immediate liquidity, while the cash ratio (48.23%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio226.27%
Quick Ratio81.49%
Cash Ratio48.23%

Profitability Ratios

002399.SZ profitability indicators offer a lens into its earnings landscape. A pretax profit margin of -11.16% underscores its earnings before tax deductions. The effective tax rate stands at 18.11%, revealing its tax efficiency. The net income per EBT, 113.19%, and the EBT per EBIT, 134.08%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of -8.32%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin-11.16%
Effective Tax Rate18.11%
Net Income per EBT113.19%
EBT per EBIT134.08%
EBIT per Revenue-8.32%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 2.26, it details the span from stock purchase to revenue. The 1 days it takes to settle debts showcases its creditor relations.

cards.indicatorcards.value
Days of Sales Outstanding81
Days of Inventory Outstanding622
Operating Cycle704.98
Days of Payables Outstanding35
Cash Conversion Cycle670
Receivables Turnover4.38
Payables Turnover10.47
Inventory Turnover0.59
Fixed Asset Turnover2.10
Asset Turnover0.29

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, 1.03, and free cash flow per share, 0.72, depict cash generation on a per-share basis. The cash per share value, 1.71, showcases liquidity position. A payout ratio of -0.56 highlights the portion of earnings distributed as dividends. Lastly, the operating cash flow sales ratio, 0.27, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share1.03
Free Cash Flow per Share0.72
Cash per Share1.71
Payout Ratio-0.56
Operating Cash Flow Sales Ratio0.27
Free Cash Flow to Operating Cash Flow Ratio0.70
Cash Flow Coverage Ratio0.31
Short Term Coverage Ratio0.48
Capital Expenditure Coverage Ratio3.35
Dividend Paid and Capex Coverage Ratio1.80
Dividend Payout Ratio0.02

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 25.73%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.40, we discern the balance between debt and equity financing. The long-term debt to capitalization, 12.43%, and total debt to capitalization, 28.71%, ratios shed light on its capital structure. An interest coverage of -2.21 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio25.73%
Debt Equity Ratio0.40
Long Term Debt to Capitalization12.43%
Total Debt to Capitalization28.71%
Interest Coverage-2.21
Cash Flow to Debt Ratio0.31
Company Equity Multiplier1.56

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 3.70, provides a glimpse into top-line earnings distributed across each share. Net income per share, -0.53, reflects the portion of profit attributed to each share. The book value per share, 8.12, represents the net asset value distributed per share, while the tangible book value per share, 6.27, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share3.70
Net Income Per Share-0.53
Book Value Per Share8.12
Tangible Book Value Per Share6.27
Shareholders Equity Per Share8.12
Interest Debt Per Share3.88
Capex Per Share-0.30

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, -24.27%, indicates top-line expansion, while the gross profit growth, -28.23%, reveals profitability trends. EBIT growth, -122.90%, and operating income growth, -122.90%, offer insights into operational profitability progression. The net income growth, -207.68%, showcases bottom-line expansion, and the EPS growth, -206.00%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth-24.27%
Gross Profit Growth-28.23%
EBIT Growth-122.90%
Operating Income Growth-122.90%
Net Income Growth-207.68%
EPS Growth-206.00%
EPS Diluted Growth-206.00%
Dividends per Share Growth69.67%
Operating Cash Flow Growth162.30%
Free Cash Flow Growth102.71%
10-Year Revenue Growth per Share212.59%
5-Year Revenue Growth per Share-4.29%
3-Year Revenue Growth per Share-6.22%
10-Year Operating CF Growth per Share-2.31%
5-Year Operating CF Growth per Share-40.01%
3-Year Operating CF Growth per Share1066.13%
10-Year Net Income Growth per Share-315.33%
5-Year Net Income Growth per Share-208.05%
3-Year Net Income Growth per Share-170.53%
10-Year Shareholders Equity Growth per Share30.14%
5-Year Shareholders Equity Growth per Share66.88%
3-Year Shareholders Equity Growth per Share-5.03%
10-Year Dividend per Share Growth per Share-22.62%
5-Year Dividend per Share Growth per Share41.88%
3-Year Dividend per Share Growth per Share-12.22%
Receivables Growth-21.48%
Inventory Growth-2.77%
Asset Growth-7.74%
Book Value per Share Growth-3.23%
Debt Growth-13.94%
R&D Expense Growth-31.33%
SGA Expenses Growth36.37%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 20,951,904,209, captures the company's total value, considering both debt and equity. Income quality, -0.60, assesses the reliability of reported earnings. The sales, general, and administrative to revenue ratio, 0.08, gauges operational efficiency, while the research and development to revenue, 3.19%, highlights investment in innovation. The ratio of intangibles to total assets, 14.66%, indicates the value of non-physical assets, and capex to operating cash flow, -94.38%, measures reinvestment capability.

cards.indicatorcards.value
Enterprise Value20,951,904,209
Income Quality-0.60
Sales General and Administrative to Revenue0.08
Research and Development to Revenue3.19%
Intangibles to Total Assets14.66%
Capex to Operating Cash Flow-94.38%
Capex to Revenue-8.21%
Capex to Depreciation-115.65%
Graham Number9.88
Return on Tangible Assets-4.78%
Graham Net Net-0.30
Working Capital5,617,724,222
Tangible Asset Value9,203,622,042
Net Current Asset Value3,419,702,723
Average Receivables1,737,594,011.5
Average Payables364,827,831
Average Inventory6,749,008,630.5
Days Sales Outstanding103
Days Payables Outstanding29
Days of Inventory On Hand648
ROIC-1.10%
ROE-0.07%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 1.28, and the price to book ratio, 1.28, reflect the market's valuation relative to the company's book value. The price to sales ratio, 2.51, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, 13.07, and price to operating cash flows, 10.22, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio1.28
Price to Book Ratio1.28
Price to Sales Ratio2.51
Price Cash Flow Ratio10.22
Price Earnings to Growth Ratio-0.54
Enterprise Value Multiple-28.32
Price Fair Value1.28
Price to Operating Cash Flow Ratio10.22
Price to Free Cash Flows Ratio13.07
Price to Tangible Book Ratio1.45
Enterprise Value to Sales3.86
Enterprise Value Over EBITDA167.99
EV to Operating Cash Flow44.45
Earnings Yield-4.54%
Free Cash Flow Yield0.15%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (002399.SZ) on the SHZ in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is -22.154 in 2024.

What is the ticker symbol of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. stock?

The ticker symbol of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. stock is 002399.SZ.

What is company IPO date?

IPO date of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. is 2010-05-06.

What is company current share price?

Current share price is 10.370 CNY.

What is stock market cap today?

The market cap of stock today is 13660292001.000.

What is PEG ratio in 2024?

The current -0.538 is -0.538 in 2024.

What is the number of employees in 2024?

In 2024 the company has 2080.